Selective Antibacterial Compounds for Bovine Respiratory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bovine and swine respiratory diseases, particularly those caused by Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, face challenges due to antibiotic resistance and the need for compounds that are specific to these pathogens without affecting human health-relevant bacteria.
Innovation Solution
Development of compounds according to specific chemical formulas that are effective against Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni, while avoiding activity against human health-relevant bacteria such as Staphylococcus spp. and Streptococcus spp., including stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad spectrum antibiotics are used to treat BRD, then bacterial infections are eliminated, but antibiotic resistance develops and human health-relevant bacteria are affected
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I and II) that possess tailored chemical properties enabling selective interaction with target bacteria. The compounds contain specific functional groups and structural features that confer selectivity against Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni while sparing human health-relevant bacteria, thus achieving localized effectiveness without broad-spectrum impact
Solution Approach 2:
The patent employs parameter changes by modifying key chemical parameters including molecular weight (150-500 Daltons), logP values (0.5-3.0), and specific functional group configurations. These parameter optimizations enable the compounds to achieve optimal balance between solubility, membrane permeability, and selective binding affinity to target bacteria, resolving the contradiction between effectiveness and selectivity
2Object-affected harmful factors
If selective compounds are developed to target specific bacteria, then human health bacteria are protected, but development complexity and time increase
Solution Approach 1:
The patent applies preliminary action by conducting extensive in silico screenings and in vitro validations during the compound design phase. The compounds undergo preliminary testing against panels of target and non-target bacteria before clinical use, establishing their selective profile upfront. This preliminary characterization accelerates subsequent development by pre-validating selectivity, thereby reducing overall development complexity despite initial screening requirements
Solution Approach 2:
The patent achieves universality by designing compounds with broad applicability across multiple veterinary species and resistance scenarios. The same compound formulations can treat different BRD-causing bacteria and are applicable across cattle, swine, and other livestock, reducing the need for species-specific developments and simplifying the overall development pipeline through multi-functional designs
Data Source
AI summary
The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).